dc.contributor.author | Hastie, KM | |
dc.contributor.author | Li, H | |
dc.contributor.author | Bedinger, D | |
dc.contributor.author | Schendel, SL | |
dc.contributor.author | Dennison, SM | |
dc.contributor.author | Li, K | |
dc.contributor.author | Rayaprolu, V | |
dc.contributor.author | Yu, X | |
dc.contributor.author | Mann, C | |
dc.contributor.author | Zandonatti, M | |
dc.contributor.author | Diaz Avalos, R | |
dc.contributor.author | Zyla, D | |
dc.contributor.author | Buck, T | |
dc.contributor.author | Hui, S | |
dc.contributor.author | Shaffer, K | |
dc.contributor.author | Hariharan, C | |
dc.contributor.author | Yin, J | |
dc.contributor.author | Olmedillas, E | |
dc.contributor.author | Enriquez, A | |
dc.contributor.author | Parekh, D | |
dc.contributor.author | Abraha, M | |
dc.contributor.author | Feeney, E | |
dc.contributor.author | Horn, GQ | |
dc.contributor.author | CoVIC-DB team1, | |
dc.contributor.author | Aldon, Y | |
dc.contributor.author | Ali, H | |
dc.contributor.author | Aracic, S | |
dc.contributor.author | Cobb, RR | |
dc.contributor.author | Federman, RS | |
dc.contributor.author | Fernandez, JM | |
dc.contributor.author | Glanville, J | |
dc.contributor.author | Green, R | |
dc.contributor.author | Grigoryan, G | |
dc.contributor.author | Lujan Hernandez, AG | |
dc.contributor.author | Ho, DD | |
dc.contributor.author | Huang, K-YA | |
dc.contributor.author | Ingraham, J | |
dc.contributor.author | Jiang, W | |
dc.contributor.author | Kellam, P | |
dc.contributor.author | Kim, C | |
dc.contributor.author | Kim, M | |
dc.contributor.author | Kim, HM | |
dc.contributor.author | Kong, C | |
dc.contributor.author | Krebs, SJ | |
dc.contributor.author | Lan, F | |
dc.contributor.author | Lang, G | |
dc.contributor.author | Lee, S | |
dc.contributor.author | Leung, CL | |
dc.contributor.author | Liu, J | |
dc.contributor.author | Lu, Y | |
dc.contributor.author | MacCamy, A | |
dc.contributor.author | McGuire, AT | |
dc.contributor.author | Palser, AL | |
dc.contributor.author | Rabbitts, TH | |
dc.contributor.author | Rikhtegaran Tehrani, Z | |
dc.contributor.author | Sajadi, MM | |
dc.contributor.author | Sanders, RW | |
dc.contributor.author | Sato, AK | |
dc.contributor.author | Schweizer, L | |
dc.contributor.author | Seo, J | |
dc.contributor.author | Shen, B | |
dc.contributor.author | Snitselaar, JL | |
dc.contributor.author | Stamatatos, L | |
dc.contributor.author | Tan, Y | |
dc.contributor.author | Tomic, MT | |
dc.contributor.author | van Gils, MJ | |
dc.contributor.author | Youssef, S | |
dc.contributor.author | Yu, J | |
dc.contributor.author | Yuan, TZ | |
dc.contributor.author | Zhang, Q | |
dc.contributor.author | Peters, B | |
dc.contributor.author | Tomaras, GD | |
dc.contributor.author | Germann, T | |
dc.contributor.author | Saphire, EO | |
dc.date.accessioned | 2022-01-07T14:13:48Z | |
dc.date.available | 2022-01-07T14:13:48Z | |
dc.date.issued | 2021-10-22 | |
dc.identifier.citation | Science (New York, N.Y.), 2021, 374 (6566), pp. 472 - 478 | |
dc.identifier.issn | 0036-8075 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4952 | |
dc.identifier.eissn | 1095-9203 | |
dc.identifier.doi | 10.1126/science.abh2315 | |
dc.description.abstract | Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propagated in human-to-human transmission and spillover or spillback events between humans and animals. To develop prevention and therapeutic strategies, we formed an international consortium to map the epitope landscape on the SARS-CoV-2 spike protein, defining and structurally illustrating seven receptor binding domain (RBD)–directed antibody communities with distinct footprints and competition profiles. Pseudovirion-based neutralization assays reveal spike mutations, individually and clustered together in variants, that affect antibody function among the communities. Key classes of RBD-targeted antibodies maintain neutralization activity against these emerging SARS-CoV-2 variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy. | |
dc.format | Print-Electronic | |
dc.format.extent | 472 - 478 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER ASSOC ADVANCEMENT SCIENCE | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | CoVIC-DB team1 | |
dc.title | Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-09-01 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1126/science.abh2315 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Science (New York, N.Y.) | |
pubs.issue | 6566 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics | |
pubs.publication-status | Published | |
pubs.volume | 374 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Chromosomal Translocations and Intracellular Antibody Therapeutics | |
dc.contributor.icrauthor | Rabbitts, Terence | |